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Background: Pancreatic leaks and ﬁstulae are common after distal pancreatectomy. The aim of this study was to determine effectiveness of prophylactic
pancreatic duct (PD) stents on leak rate following distal pancreatectomy.
Methods: A meta-analysis of ﬁve studies including 218 patients. PD stents were placed endoscopically in two studies and intraoperatively in three studies.
Octreotide was given postoperatively in one study.
Results: No signiﬁcant difference in leak rates was seen with PD stents; however, when the study that also used Octreotide was removed, PD stents were
favorable.
Conclusion: Placement of PD stents for prevention of PD leaks and ﬁstulae following distal pancreatectomy cannot be routinely recommended.
Copyright  2013, Society of Gastrointestinal Intervention. Published by Elsevier. All rights reserved.
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Intraoperative placement of ductal stents to prevent post-
operative leaks and ﬁstulae has been a mainstay of resective
pancreatic surgery (pancreaticoduodenectomy).1,2 In addition,
endoscopic placement of pancreatic duct (PD) stents is effective for
the treatment of postoperative PD leaks following distal pancrea-
tectomy.3 Stent placement promotes leak closure by abolishing the
pressure gradient at the level of the sphincter, thus diverting
pancreatic juice from the leak site. Similarly, the concept of pre-
operative placement of PD stents should theoretically prevent PD
leaks in patients undergoing distal pancreatectomy, and has
recently been studied.4 Randomized controlled trials and compar-
ative cohort studies on placement of PD stents to prevent leaks
have yielded mixed results. We performed a meta-analysis to
determine the effectiveness of PD stents in the prevention of PD
leaks following distal pancreatectomy.
Methods
Literature search
We performed a computer-assisted literature search of Medline,
Ovid SP, EMBASE, and Web of Science to identify all human studies
published in the English literature of peer- reviewed medical
journals up until July 2012 comparing outcomes of PD stentingDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
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stenting in patients undergoing distal pancreatectomy for any
indication. We used the following medical subject heading terms:
pancreatectomy, pancreatic surgery, and ﬁstula. Relevant papers
were also identiﬁed from the bibliography of papers obtained
through the search.
Study selection
We reviewed titles and abstracts of the search ﬁndings for po-
tential eligibility into the meta-analysis. We included studies that
provided comparative data on the rate of pancreatic ﬁstula after
distal pancreatectomy in patients with or without prophylactic PD
stent placement. Two reviewers performed study selection
(B.K.A.D. and S.A.); when a disagreement occurred, a third blinded
reviewer (T.H.B.) was consulted to resolve the disagreement. Both
reviewers eventually agreed on all included studies.
Inclusion and exclusion criteria
For inclusion in the meta-analysis, a study had to meet the
following inclusion criteria: human trial, published in English in a
peer-reviewed journal, and comparison of the outcomes of patients
who underwent distal pancreatectomy with prophylactic PD stent
placement (regardless of whether the stent was placed endoscop-
ically prior to the surgery or intraoperatively) to the outcomes of0 First Street SW, Rochester, MN 55905, USA.
on. Published by Elsevier. All rights reserved.
Fig. 1. Literature search leading to the ﬁve studies included in the meta-analysis.
Table 1 Studies Included in the Meta-analysis
Study PD stent/leaks (%) Control/leaks (%)
Frozanpor et al 20128 26/13 (50) 27/10 (37)
Oida et al 20119 15/1 (6.7) 25/8 (32)
Rieder et al 201011 25/0 (0) 23/5 (22)
Fischer et al 20087 16/1 (6.3) 43/14 (33)
Okamoto et al 200810 7/3 (42) 11/3 (27)
Total 89/18 (20) 129/40 (31)
PD, pancreatic duct.
Barham K. Abu Dayyeh et al. / Placement of pancreatic stents 109patients who underwent distal pancreatectomy without prophy-
lactic PD stent placement.
Abstracts, letters, editorials, expert opinions, reviews without
original data, case reports, and studies lacking a control groupwere
excluded from the meta-analysis. All prospective randomized trials
included met the majority of the criteria set forth by the Evidence-
Based Gastroenterology Steering Group for methodologic quality
indicating reasonable quality.5
Data extraction
Two independent reviewers performed data extraction from
each selected study. When ambiguity on outcome determination
was present, a third reviewer was consulted and the outcome was
determined by consensus. The primary outcome measured was
the development of postoperative pancreatic ﬁstula formation as
deﬁned by the International Study Group on Pancreatic Fistula
(i.e., the presence of amylase-rich ﬂuid greater than three times
the upper limit of normal in the serum of any measurable volume
on or after Day 3).6 Secondary outcomes were inconsistently re-
ported and included postoperative morbidities, intra-abdominal
ﬂuid collections, hospital stay, duration to drain removal, opera-
tive time, gastric emptying, death, and PD stent-related adverse
events.
Statistical analysis
To best summarize the available evidence, we conducted direct
meta-analyses comparing the rates of pancreatic ﬁstula formation
after distal pancreatectomy with PD stenting (whether placed
endoscopically or intraoperatively) versus no stenting. We calcu-
lated the pooled odds ratio with 95% conﬁdence intervals (CI) using
ﬁxed and random-effects models. Statistical heterogeneity was
evaluated by means of I2 statistics; an I2 value of more than 50%
was considered to indicate high statistical heterogeneity. A funnel
plot and Egger regression asymmetry were used to assess for po-
tential publication bias. Analyses were performed using the
comprehensive Meta-analysis software version 2 (Biostat, Engle-
wood, NJ, USA).
Results
The literature search revealed a total of 2805 references. There
were 2614 references that were excluded based on review of the
title or duplication of the citation; subsequently, 191 abstracts were
reviewed, which resulted in 178 abstract being excluded because
they did not meet the inclusion criteria. The remaining 13 articles
were fully reviewed and eight of these articles were excluded
because they did not meet inclusion criteria. The remaining ﬁve
articles were included in the study (Fig. 1).7–11 These ﬁve studies
were published between 2008 and 2012 (Table 1).7–11 Two studies
were conducted in Japan, one study in Sweden, one study in Ger-
many, and one in the United States.
In two studies, patients had endoscopic PD stents placed pre-
operatively,10,11 and in three studies the stents were placed intra-
operatively.7–9 Two studies were retrospective,7,9 two were
prospective,8,10 and one was prospective with a retrospective con-
trol group.11 The prospective studies were not blinded, and only one
was randomized.8
The sizes of PD stents used were 5 French or 7 French in three
studies,8,10,11 pediatric feeding tubes without mention of size were
used in one study,7 and no report of PD stents sizes in one study.9
One study coadministered octreotide at 100 mg subcutaneously
preoperatively, and continued every 8 hours until oral feeding was
resumed.8The number of patients in these studies ranged from 18 to 59.
The total number of patients in all ﬁve studies was 218; 89 patients
had PD stents placed and 129 patients did not. The deﬁnition of
pancreatic ﬁstula proposed by the International Study Group on
Pancreatic Fistula was used in all ﬁve studies. In the PD stent group,
PD ﬁstula occurred in 0–50% of patients compared to the no stent
group, in whom the incidence of PD ﬁstula ranged from 22% to 37%
(Table 1). Clinically signiﬁcant ﬁstulas (grade B and C) were only
reported in four studies (Table 2).7–11Meta-analysis of the primary outcome
Meta-analysis of the ﬁve studies failed to show a signiﬁcant
difference in the rate of postoperative ﬁstula formation between
the two groups with an odds ratio (OR), 95% conﬁdence interval,
(CI), and P-value (P) of 0.8 (CI 0.35–1.96, P ¼ 0.6) and 0.45 (CI 0.09–
2.2, P¼ 0.3) using the ﬁxed and random effectsmodels, respectively
(Fig. 2). There was a signiﬁcant degree of heterogeneity among the
studies (I2 63%, P ¼ 0.03), and there was no evidence of publication
bias based on review of the funnel plot (Fig. 3).
Three studies were in favor of prophylactic PD stent place-
ment,7,9,11 and two studies were in favor of no stent placement.8,10
Table 2 Detailed Information on Grades B and C Fistulae in the PD Stent Group
vs. Controls
Study PD stent group Control group
Total no.
of ﬁstulae
Grades B &
C ﬁstulae
Total no.
of ﬁstulae
Grades B &
C ﬁstulae (%)
Frozanpor et al 20128 13 11 10 6
Oida et al 20119 1 0 8 8
Rieder et al 201011 0 0 5 3
Fischer et al 20087 1 Not mentioned 14 Not mentioned
Okamoto et al 200810 3 2 3 2
PD, pancreatic duct.
Gastrointestinal Intervention 2013 2(2), 108–112110Only one of the studies (retrospective) showed a signiﬁcant dif-
ference (P < 0.05) in the rate of pancreatic ﬁstula formation, and it
favored PD stent placement.7
Statistics of meta-analysis were performedwith removal of each
study separately. In four studies, the results were insigniﬁcantly
changed from that of the entire meta-analysis.7,9–11 However, when
removing the study by Frozanpor et al,8 in which octreotide was
used and pancreatic stents were placed intraoperatively, PD stent
placement strategy was favored with an OR of 0.26 (CI 0.07–0.89,
P ¼ 0.03; Fig. 4).Fig. 2. Meta-analysis of th
Fig. 3. Funnel plot of the ﬁve studieSecondary outcomes
PD stent placement-related adverse events were mentioned in
four studies and summarized in Table 3.7–11 In the study by Fro-
zanpor et al,8 three of 26 patients in the PD stent group had PD
stent-related pancreatitis without any further details, and the PD
could not be cannulated in two patients. In the study by Okamoto
et al,10 two of seven patients in the PD stent group had mild
pancreatitis. In the study by Rieder et al,11 one of 25 patients in the
PD stent group had mild pancreatitis and PD stent placement was
successful in 23 patients (92%). Postoperative intra-abdominal ab-
scess formation was reported in two studies with conﬂicting re-
sults. In the study by Frozanpor et al,8 there was increased
incidence of intra-abdominal abscess formation in the PD stent
group, 11 (42%) versus ﬁve (18.5%) with P ¼ 0.0658. In the study by
Fischer et al,7 there was no signiﬁcant decrease in the incidence of
intra-abdominal abscess formation in the PD stent group compared
to control, two (12.5%) versus three (6.9%) with a nonsigniﬁcant P
value. Length of hospital stay was reported in three studies. A
longer stay in the PD stent group was shown in one study,8 a
shorter stay in the PD stent group in a second study,7 and no dif-
ference in length of stay in the third study (Table 3).11e primary outcome.
s included in the meta-analysis.
Fig. 4. Meta-analysis after exclusion of each study separately.
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Endoscopic stent placement for the treatment of bile leaks has
become an accepted non-surgical therapy as biliary endoprostheses
divert ﬂow away from the leak site and abolish the high pressure
gradient at the level of the biliary sphincter. Similarly, placement of
PD stents has become an established therapy for PD leaks and
ﬁstulae from both surgical and nonsurgical causes.3,12–14 The
concept of prevention of leaks following resective pancreatic sur-
gery, particularly pancreaticoduodenectomy (Whipple procedure)
has been attempted for many years, though recent data have not
shown them to be of deﬁnitive beneﬁt.1,15
Using meta-analytic methods, we examined the effect of pre-
operative (2 studies)10,11 or intraoperative transpapillary placement
of PD stents (3 studies)7–9 on postoperative leak rates following
distal pancreatectomy. Meta-analysis of the ﬁve studies failed to
show a signiﬁcant difference in the rate of postoperative ﬁstula
formation between patients with prophylactic PD stents versus
patients with no PD stents.
Howdoesonereconcile thatpostoperativeplacementofPDstents
effectively closes leaks yet a preoperative stent placement does not
prevent leaks? Perhaps stents diameters are not large enough
compared to the size of the leak. The main PD in most patients un-
dergoing distal pancreatectomy is small in diameter and often does
not permit placement of stents larger than 5 French in diameter.
Indeed, 5-French stents were placed in the majority of patients.
The other way to explain why prophylactic PD stent placement
did not show a beneﬁt is to examine the results of this meta-
analysis after excluding the single study in which octreotide was
used. Although separately excluding the four studies in which
octerotide was not used did not change the outcomes of the meta-
analysis, excluding the study by Frozanpor et al,8 in which octero-
tide was used, showed a statistically signiﬁcant difference in the
rate of postoperative ﬁstula formation favoring PD stent placement.Table 3 Secondary Outcomes Including PD Stent Related Complications
Study Pancreatitis in
PD stent
group (n/total)
Length of
hospital stay
Abdominal abscess
formation (PD stent
vs. control)
n(%) P
Frozanpor
et al 20128
3/26 Longer in the
PD stent group
11 (42) vs. 5
(18.5)
0.065
Oida et al 20119 Not mentioned Not mentioned Not mentioned
Rieder et al 201011 1/25 (mild) Similar stay in
both groups
Not mentioned
Fischer
et al 20087
Not mentioned Not mentioned 2 (12.5) vs. 3
(6.9)
NS
Okamoto
et al 200810
2/7 (mild) Shorter in the
PD stent group
Not mentioned
PD, pancreatic duct.These ﬁndings suggest that octerotide use may somehow confound
the results of the meta-analysis, and prophylactic PD stent place-
ment alone helps to reduce the rate of postoperative pancreatic
ﬁstula formation after distal pancreatectomy.
Octreotide is a synthetic analogof endogenous somatostatinwith
more potency and longer half-life.16–18 Octreotids exerts its effects
by inhibitingpancreatic exocrine secretion,16–18 and thismechanism
has been proposed to reduce the rate of pancreatic ﬁstula after
pancreatic resection.16 Several clinical trials and reviews have
evaluated the use of octreotide to prevent the development of
pancreatic ﬁstula after pancreatic surgery.19 The prophylactic use of
perioperative somatostatin and its analogs to prevent postoperative
pancreatic ﬁstula remains controversial and does not result in a
reduction of surgical mortality.20 In a meta-analysis by Alghamdi
and colleagues19 that included seven studies, there was no signiﬁ-
cant reduction in the rate of pancreatic ﬁstula formation or post-
operative mortality in the group that received octreotide. The
authors of this meta-analysis noted contradictory results between
European and American studies included in the meta-analysis with
higher incidence of ﬁstula formation in the placebo group of Euro-
pean studies compared to American ones. In another study, pro-
phylactic octerotide after pancreatic surgery did not affect the
severity of postoperative pancreatic ﬁstula.21
Our study represents the ﬁrst meta-analysis in the literature
speciﬁcally assessing the value of prophylactic PD stent placement
prior to distal pancreatectomy. We found similar meta-analysis in
the literature, but they included patients with pan-
creaticoduodenectomy and pancreaticojejunostomy.1,15
Limitations of this meta-analysis included the small number of
patients ineachstudy, the inconsistent reportingof theadverseevents
associated with distal pancreatectomy, and PD stent placement.
In conclusion, the results of this meta-analysis did not show a
signiﬁcant difference in the rate of postoperative ﬁstula formation
after distal pancreatectomy when prophylactic PD stents were
placed, but exclusion of patients who received octerotide showed
signiﬁcant ﬁndings favoring prophylactic PD stent placement. More
evidence from randomized studies is needed including an investi-
gation of the effect of perioperative octerotide on ﬁstula formation
in the presence or absence of prophylactic PD stents.
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